A new report from Ireland’s Joint Oireachtas Committee on Health and Children makes a number of important recommendations that are intended to reduce the long-term cost of pharmaceutical drugs, and increase the use of generic drugs in Ireland.
This is timely, given that the 2012–2015 agreement between the Health Services Executive (HSE) and pharmaceutical companies is due for renewal. The Committee has presented the report to Minister for Health, Leo Varadkar.
Some of the Report’s main conclusions and recommendations include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze